Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 18/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654216 | 0.91 | NPY2R (0.60) | NPY2R | |
| SCHEMBL3661651 | 0.90 | NPY2R (0.67) | NPY2R | |
| SCHEMBL13884190 | 0.88 | NPY2R (0.56) | NPY2RMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8736279 | 0.87 | NPY2R (0.54) | NPY2RMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL3651437 | 0.82 | NPY2R (0.77) | NPY2R | |
| SCHEMBL13883808 | 0.79 | NPY2R (0.62) | NPY2RMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3658778 | 0.79 | NPY2R (0.63) | NPY2R | |
| SCHEMBL6116051 | 0.78 | NPY2R (0.60) | NPY2RMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4008950 | 0.78 | NPY2R (0.65) | NPY2R | |
| SCHEMBL8737593 | 0.76 | NPY2R (0.56) | NPY2RMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205561-A2 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050197-A2 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050197-A2 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099199-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090099199-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20090099199-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099199-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLC10A6, SLCO1B1 | NPY2R 2590/4885MEN1 235/4885ALDH1A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.